Remedy and preventive for diseases caused by NF-κB

Details Remedy and preventive for diseases caused by NF-κB Remedy and preventive for diseases caused by NF-κB

2011-01-18

2011-01-18

McGarry, Sean (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07871983

ABSTRACT:
Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF-κB is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF-κB, such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia.

REFERENCES:
patent: 5591840 (1997-01-01), Narayanan et al.
patent: 6262033 (2001-07-01), Morishita et al.
patent: 6399376 (2002-06-01), Melford et al.
patent: 6410516 (2002-06-01), Baltimore et al.
patent: 2102704 (1992-11-01), None
patent: 2131587 (1995-03-01), None
patent: 589330 (1994-03-01), None
patent: 0 824 918 (1998-02-01), None
patent: 6-209778 (1993-09-01), None
patent: 06/508029 (1994-09-01), None
patent: 07/114990 (1995-05-01), None
patent: 07/170998 (1995-07-01), None
patent: 07/285504 (1995-11-01), None
patent: 95/12415 (1995-05-01), None
patent: WO 95/11687 (1995-05-01), None
Toshiba Nakajima et al., Involvement of NF-kB Activation in Throwbin-Induced Human Vascular Smooth Muscle Cell Proliferation, Biochem and Biophysical Research Communication, Oct. 1994, p. 950-955, vol. 204, No. 2.
Anna Beilinski et al. Regulation of Gene Expression with Double-Stranded Phosporothioate Oligoonucleotides, Science, Nov. 1990, vol. 250, p. 997-1000.
Sokoloski et al., Antisense Oligonucleotides to the p65 Subnunit of NF-kB Block CD11b Expression and Alter Adhesion Properties of Differentiated HL-60 Granulocytes, Blood, Jul. 1993, vol. 82, No. 2, p. 625-632.
N. Tomita et al., “A Novel Strategy for Gene Therapy and Gene Regulation Analysis Using Transcription Factor Decoy Oligonucleotides”, EXP. Nephrol 1997; 5:429-434.
I. Kawamura et al., “Intratumoral Injection of Oligonucleotides to the NFkB Binding Site Inhibits Cachexia In A Mouse Tumor Model”, Gene Therapy (1999)6, 91-97.
N. Tomita et al., “Transcription Factor Decoy for Nuclear Factor-κB Inhibits Tumor Necroses Factor-α-Induced Expression of Inteerleukin-6 and Tracellular Adhesion Molecule-1 in Endothelial Cells”, Journal of Nypertension 1998, 16:993-1000.
T. Tomita et al., “Suppressed Severity of Collagen-Induced Arthritis by In Vivo Transfection of Nuclear Factor kB Decoy Oligodeoxynucleotides As A Gene Therapy”, Arthritis & Rheumatism, vol. 42, No. 12, Dec. 1999.
Kaltschmidt et al., “Transcription factor NF-KB is activated in microglia during experimental autoimmune encephalomyelitis,”J. Neuroimmun., 1994, vol. 55: pp. 99-106.
Higgins et al., “Antisense inhibition of the p65 subunit of NF-KB blocks tumorigenicity and causes tumor regression,”PNAS, Nov. 1993, vol. 90: pp. 9901-9905.
Neish et al., “Functional Analysis of the Human Vascular Cell Adhesion Molecule 1 Promotor,”J. Exp. Med., Dec. 1992, vol. 176: pp. 1583-1593.
Menetski, J. Biol. Chem. 275: 7619-25 (2000).
Deok et al., Circ. Res. 90: 1325-32 (2002).
Crinelli et al., Nucl. Acids Res. 30: 2435-43 (2002).
Morishita et al., “Oligonucleotide-Based Gene Therapy for Cardiovascular Disease,”Clin. Chem. Lab. Med., 1998, vol. 36(8): pp. 529-534.
Nakamura et al., “Prevention and regression of atopic dermatitis by ointment containing NF-κB decov oligodeoxynucleotides in NC/Nga atopic mouse model,”Gene Therapy, Sep. 2002, vol. 9, pp. 1221-1229.
Kawamura, et al., “Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice,”Gene Therapy, Jun. 2001, vol. 8(12): 905-12.
Tomita et al., “Inhibition of TNF alpha, induced cytokine and adhesion molecule. Expression in glomerular cells in vitro and in vivo by transcription factor decoy for Exp. Nephrol.,”Exp. Nephrol., 2001, vol. 9(3), pp. 181-190.
Tomita et al., “In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis,”J. Am. Soc. Nephrol., 2000, vol. 11: pp. 1244-1252.
Suzuki et al., “Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts,”Gene Therapy, Nov. 2000, vol. 7(21): pp. 1847-1852.
Tomita et al., “Transcription factor decoy for NFkappaB inhibits cytokine and adhesion molecule expressions in svnovial cells derived from rheumatoid arthritis.,”Rheumatology(Oxford), Jul. 2000, vol. 39(7): pp. 749-757.
Tomita et al., “Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy,”Arthritis&Rheum..1999, vol. 42, pp. 2532-2542.
Matsushita et al., “Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF-kappaB)-medicated bcl-2 suppression: in vivo evidence of the importance of NF-kappaB in endothelial cell regulation,”Circulation Res., May 2000, vol. 86(9): pp. 974-981.
Sawa et al., Circulation, 96 (Supp. II) 280-84 (1997).
Kawamura et al., “Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model,”Gene Therapy, Jan. 1999, vol. 6(1): pp. 91-97.
Tomita et al., “Transcription factor decoy for nuclear factor-kappaB inhibits tumor necrosis factor-alpha-induced expression of interleukin-6 and intracellular adhesion molecule-1 in endothelial cells,” J. Hypertension, Jul. 1998, vol. 16: pp. 993-1000.
Morishita et al., “In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction,”Nature Med., Aug. 1997, vol. 3(8): pp. 894-899.
Nakajima, et al., “Involvement of NF-KB Activation in Thrombin Induced Human Vascular Smooth Muscle Cell Proliferation,”Biochem. Biophys, Oct. 1994, vol. 204(2): pp. 950-955.
Sawa, et al., “A Novel Strategy for Myocardial Protection Using in Vivo Transfection of CIS Element “Decoy” Against NFκB Binding Site,”Circulation, Nov. 1997, vol. 96(9), pp. 11-281-11-285.
Morishita, et al., “Application of Transcription Factor “Decoy” Strategy As Means of Gene Therapy and Study of Gene Expression Cardiovascular Disease,”Cir. Res., 1998, vol. 82, pp. 1023-1028.

Affiliated with

Also associated with

Rating

Remedy and preventive for diseases caused by NF-κB does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Remedy and preventive for diseases caused by NF-κB, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Remedy and preventive for diseases caused by NF-κB will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2710414